EMA Backs Breast Cancer SERD After FDA No Vote

Published Date: 23 May 2026

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Read Full News

Latest News

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Latest News

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

News All Time

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Recommended News For You

Prior authorizations draining time, energy from many cancer patients

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Mezigdomide Combinations Show Promise in Multiple Myeloma

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

Recommended Articles For You

Unraveling the Mysteries of Lymphoma: A Journey into the Unknown 

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment 

Cancer Rates on the Rise: What Can We Do to Stop It? 

Understanding Dasatinib: A Promising Drug for Cancer Treatment  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antibiotic Stewardship: Five Tips to Reduce Resistance

2.

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

3.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

4.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

5.

EMA Backs Breast Cancer SERD After FDA No Vote

1.

Exploring the Latest Treatments for Essential Thrombocythemia

2.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

3.

Treating Methemoglobinemia: What You Need to Know Now!

4.

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications

5.

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

2.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

Updates on the First Line Management of ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot